These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Buprenorphine effects on plasma luteinizing hormone and prolactin in male heroin addicts. Mendelson JH; Ellingboe J; Mello NK; Kuehnle J J Pharmacol Exp Ther; 1982 Feb; 220(2):252-5. PubMed ID: 7057390 [TBL] [Abstract][Full Text] [Related]
26. Different profiles of buprenorphine-induced analgesia and antihyperalgesia in a human pain model. Koppert W; Ihmsen H; Körber N; Wehrfritz A; Sittl R; Schmelz M; Schüttler J Pain; 2005 Nov; 118(1-2):15-22. PubMed ID: 16154698 [TBL] [Abstract][Full Text] [Related]
27. Mu-opioid receptor binding measured by [11C]carfentanil positron emission tomography is related to craving and mood in alcohol dependence. Bencherif B; Wand GS; McCaul ME; Kim YK; Ilgin N; Dannals RF; Frost JJ Biol Psychiatry; 2004 Feb; 55(3):255-62. PubMed ID: 14744466 [TBL] [Abstract][Full Text] [Related]
28. Opioid receptor imaging with positron emission tomography and [(18)F]cyclofoxy in long-term, methadone-treated former heroin addicts. Kling MA; Carson RE; Borg L; Zametkin A; Matochik JA; Schluger J; Herscovitch P; Rice KC; Ho A; Eckelman WC; Kreek MJ J Pharmacol Exp Ther; 2000 Dec; 295(3):1070-6. PubMed ID: 11082442 [TBL] [Abstract][Full Text] [Related]
29. Increased mu opioid receptor binding detected by PET in cocaine-dependent men is associated with cocaine craving. Zubieta JK; Gorelick DA; Stauffer R; Ravert HT; Dannals RF; Frost JJ Nat Med; 1996 Nov; 2(11):1225-9. PubMed ID: 8898749 [TBL] [Abstract][Full Text] [Related]
30. Interactions between the discriminative stimulus effects of mu and kappa opioid agonists in the squirrel monkey. Negus SS; Picker MJ; Dykstra LA J Pharmacol Exp Ther; 1991 Jan; 256(1):149-58. PubMed ID: 1846412 [TBL] [Abstract][Full Text] [Related]
31. Smoking modulation of mu-opioid and dopamine D2 receptor-mediated neurotransmission in humans. Scott DJ; Domino EF; Heitzeg MM; Koeppe RA; Ni L; Guthrie S; Zubieta JK Neuropsychopharmacology; 2007 Feb; 32(2):450-7. PubMed ID: 17091130 [TBL] [Abstract][Full Text] [Related]
32. Placebo and nocebo effects are defined by opposite opioid and dopaminergic responses. Scott DJ; Stohler CS; Egnatuk CM; Wang H; Koeppe RA; Zubieta JK Arch Gen Psychiatry; 2008 Feb; 65(2):220-31. PubMed ID: 18250260 [TBL] [Abstract][Full Text] [Related]
34. Evaluation of an injection depot formulation of buprenorphine: placebo comparison. Sigmon SC; Wong CJ; Chausmer AL; Liebson IA; Bigelow GE Addiction; 2004 Nov; 99(11):1439-49. PubMed ID: 15500597 [TBL] [Abstract][Full Text] [Related]
35. Methadone maintenance dose modulates anterior cingulate glutamate levels in heroin-dependent individuals: A preliminary in vivo (1)H MRS study. Greenwald MK; Woodcock EA; Khatib D; Stanley JA Psychiatry Res; 2015 Aug; 233(2):218-24. PubMed ID: 26188663 [TBL] [Abstract][Full Text] [Related]
36. The relationship between naloxone-induced cortisol and mu opioid receptor availability in mesolimbic structures is disrupted in alcohol dependent subjects. Wand GS; Weerts EM; Kuwabara H; Wong DF; Xu X; McCaul ME Alcohol; 2012 Sep; 46(6):511-7. PubMed ID: 22717196 [TBL] [Abstract][Full Text] [Related]
37. Characterization of the discriminative stimulus effects of buprenorphine in pigeons. Galici R; Brandt MR; France CP Psychopharmacology (Berl); 2002 Mar; 160(2):132-9. PubMed ID: 11875630 [TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of transdermal buprenorphine: a randomized, placebo-controlled trial in 289 patients with severe cancer pain. Poulain P; Denier W; Douma J; Hoerauf K; Samija M; Sopata M; Wolfram G J Pain Symptom Manage; 2008 Aug; 36(2):117-25. PubMed ID: 18411010 [TBL] [Abstract][Full Text] [Related]
39. Placebo effects on human mu-opioid activity during pain. Wager TD; Scott DJ; Zubieta JK Proc Natl Acad Sci U S A; 2007 Jun; 104(26):11056-61. PubMed ID: 17578917 [TBL] [Abstract][Full Text] [Related]
40. Gender and age influences on human brain mu-opioid receptor binding measured by PET. Zubieta JK; Dannals RF; Frost JJ Am J Psychiatry; 1999 Jun; 156(6):842-8. PubMed ID: 10360121 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]